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Background: Some infants experience excessive weight gain during exclusive
breastfeeding. The cause is unknown, but variation in humanmilk composition might play
a role. Several human milk koligosaccharides (HMOs) have been associated with growth
velocity in breastfed infants, and it has been suggested that the mechanism could be
through an effect on infant gut microbiota composition.
Objective: The purpose of this exploratory study was to evaluate if HMO composition
was different in milk fed to infants with excessive weight gain compared to infants
with normal weight gain. Furthermore, we aimed to examine if HMO composition was
associated with growth velocity and change in body composition and if there were
maternal determinants of HMO composition.
Materials andMethods: We recruited 13 high weight-gain (HW) and 17 normal weight-
gain (NW) breastfed infants, collected human milk and anthropometry data at 5 and 9
months, and analyzed HMO composition by high performance liquid chromatography.
Results: In the HW group eight out of 11 infants received milk from secretor mothers
and in the NW group 15 out of 17. Comparing milk from Secretor mothers only,
four HMO’s were significantly different between the HW and NW group at 5 months
and two remained significant at 9 months. Total HMO concentrations as well as
total HMO-bound fucose at 5 months were positively associated with both fat mass
index (FMI) and weight velocity from 0 to 5 months (all p < 0.025). 2′-fucosyllactose
(2′-FL) was positively associated with weight velocity from 0 to 5 months and FMI
at 5 months. In contrast, lacto-N-neotetraose was lower in the HW group (p =
0.012) and negatively associated with height-for-age Z-scores (p = 0.008), weight
velocity from 0 to 5 months (p = 0.009) and FMI (p = 0.033). Maternal BMI at 5
months was negatively associated with 6′-sialyllactose and sialyl-lacto-N-tetraose (LSTb)
and positively with 2′-FL, total HMO and total HMO-bound fucose (all p ≤ 0.03).
Larsson et al. HMOs and Weight-Gain During Breastfeeding
Conclusion: In a small cohort, we found significantly different HMO concentrations in
milk to exclusively breastfed infants with excessive weight gain, suggesting that some
HMOs, including 2′-FL, which is the most abundant HMO and currently added to some
infant formula, could be part of the cause for the excessive weight gain.
Keywords: growth, obesity, infancy, breastfeeding, human milk, human milk oligosaccharides, infant feeding,
infant
INTRODUCTION
Humanmilk is recommended as the optimal nutrition for infants
due to a wide range of beneficial effects for both mother and
infant (1). This includes a potential protective effect against
later overweight and obesity for the child, even though not all
studies support this view (1–3). The conflicting findings may
be partially due to the diverse composition of human milk,
which contains macronutrients, micronutrients, and a host of
bioactive compounds, some of which seem to affect growth
and body composition (4, 5). Human milk oligosaccharides
(HMOs) have recently been linked to growth in early infancy.
This was observed in 37 mother-infant dyads where an increase
in lacto-N-fucopentaose (LNFP) I was associated with lower
infant weight at 1 and at 6 months, and lower lean and fat
mass at 6 months. Further, LNFP II and disialyl-lacto-N-tetraose
(DSLNT) were associated with higher fat mass at 6 months
(6). Adding HMOs to infant formula has also gained interest
because of the potential positive effects on the microbiota and the
immune system of the infant. An intervention study adding the
HMOs 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT)
to infant formula showed lower morbidity and no effect on
growth (7). Little is known about which factors determine the
variability in HMO concentration, however, single nucleotide
polymorphisms in the fucosyltransferase 2 (FUT2) secretor
gene result in human milk that is deficient in α1,2-fucosylated
oligosaccharides. Women with an active FUT2 enzyme are
referred to as Secretors as they secrete a substantial amount
of α1,2-fucosylated oligosaccharides; women with an inactive
FUT2 that lack α1,2-fucosylated oligosaccharides are referred to
as Non-secretors.
Some exclusively breastfed infants have an excessive weight
gain in the first 6 months of life, but it is not known if the risk
of later obesity is lower in this group of infants compared to
infants breastfed less. Only a few studies have targeted this group
of infants and therefore little is known about the causes for this
excessive weight gain (8–12). Since the high weight gain occurs
during the exclusive breastfeeding period and some studies show
a noticeable catch-down after introduction to complementary
food (9–11), it is reasonable to search for answers for this growth
pattern in human milk composition itself. We have recently
shown that infants with excessive weight gain during exclusive
breastfeeding in the SKOT III cohort had a marked catch-
down in weight and BMI z-scores from 5 to 9 months, when
complementary foods were introduced (11).
Since some HMOs are related to growth, we hypothesized that
differences in HMO composition could be part of the explanation
for the early excessive weight gain seen in some exclusively
breastfed infants. To test this hypothesis, we analyzed HMO
composition in milk samples from the exploratory SKOT III
cohort of exclusively breastfed infants with excessive weight-gain
and compared the values with a group of exclusively breastfed
infants with normal weight-gain.
MATERIALS AND METHODS
Study Design and Subjects
The mother-infant dyads were part of an ongoing prospective
observational cohort study, the SKOT III cohort. The cohort
included mothers and their 4–6 months old infants in two groups
based on weight-for-age z-scores (WAZ). Infants with a WAZ
> 2 and an increment of > +1 SDS in WAZ during the
first 5 months post-partum, were recruited to a high weight-
gain group (HW-group); infants with a WAZ between −1.0 and
+1.0 SD were recruited to a normal weight-gain (NW) group.
Further inclusion criteria for both groups were exclusive or full
breastfeeding to at least 4 months post-partum. Infants in both
groups were examined at age 5–6½ months and 9 months ± 2
weeks. Recruitment and overall study design has previously been
described in detail together with human milk intake, content of
macronutrients and hormones, as well as infant growth and body
composition in the two groups (11).We did notmatch the infants
based on sex, birth weight, maternal age, parity, and mode or
place of delivery, however, the groups were overall well-matched.
The study protocol was approved by the Regional Ethical
Committee of the Capital Region of Denmark in accordance with
the Helsinki declaration (H-15008948) and the Data Protection
Agency (2015-57-0117 & 2015-57-0116) and written informed
consent was obtained from all parents.
Seventeen infants were referred according to the WAZ
inclusion criteria to the HW group. However, four infants were
excluded since they did not experience excessive weight gain
although they had a WAZ > 2SDS at the first examination.
Two infants were excluded because they had a high length and
therefore a BAZ < 2.00 and two were excluded because they
had a relatively low weight gain from birth to 5 months (their
birthweights were above 4.00 kg and changes in WAZ from
birth to 5 months were −0.16 and +0.6 and could therefore
not be defined as excessive weight gain). Thus, the HW-group
included 13 infants with at least + 1.0 SDS increment in WAZ
during the first 5–6 months post-partum. In the NW-group 42
parents showed interest in participating. Of these, 19 mother-
infant dyads fulfilled the inclusion criteria. However, two infants
were excluded. One had a low birth weight (2.67 kg; WAZ −1.3
SDS) followed by a catch-up with a WAZ increment of 1.8 SDS.
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The other one had a birth weight of 4.66 kg (WAZ +2.5 SDS)
followed by a catch down in WAZ of−2.9 SDS. Thus, the NW-
group included 17 infants with an increment in WAZ during
the first 5–6 months post-partum within normal range, defined
as <0.67 SDS.
Anthropometry
Anthropometric measurements have been described in detail
previously (11). In brief, weight and length were measured
using standard procedures. Body composition was measured
using Bioelectrical Impedance Analyzer (BIA) Quantum III (RJL
Systems, Michigan, USA) and fat free mass (FFM), fat mass (FM),
and fat mass percentage (FM%) were then calculated using the
Lingwood Equation (11, 13). Maternal pre-pregnancy BMI as
well as gestational weight gain were self-reported while maternal
weight and height were measured using standardized procedure
at the infant’s age 5 months visit (11).
24h Milk Volume
The 24 h milk intake has been explained in detail previously
(11). To measure the 24 h milk intake at 5 months, mothers
weighed their infants for a period of 72 h before and after
each breastfeeding-session (each feed) using an electronic baby
weighing scale (Tanita BD 815MA, Tanita Corporation, Tokyo,
Japan). Calculation of intake in grams was done by subtracting
weight of the infant before the feed from the weight after the
feed. In cases where test weighing was not completed for all
feeds, the intake was estimated using an average of intake per
feed calculated from the mother’s registration. No correction for
infant insensible water loss was made, and therefore the milk
intake is likely to be underestimated by 3–10% (14, 15).
Human Milk Sampling and HMO Analysis
Mothers were asked to pump the entire content of both breasts
using a manual breast pump (Type HarmonyTM, Medela AG,
Baar, Switzerland) at infant age 5–6½ months and 9 months.
The milk samples were stored at −20◦C in the homes of the
participants and transported in a bag with an ice pack and
stored at −80◦C at the University of Copenhagen. HMOs were
analyzed in well-mixed samples of right and left breast at the
University of California, San Diego, using high performance
liquid chromatography (HPLC) after fluorescent derivatization
(16). In brief, raffinose was added to the milk samples as an
internal standard to allow for absolute HMO quantification.
Oligosaccharides were isolated by solid phase extraction (SPE)
over C18 and carbograph microcolumns, derivatized with 2-
aminobenzamine (2AB), and further purified over silica gel SPE
microcolumns. 2AB-labeled HMOs were analyzed by HPLC
on an amide column with fluorescent detection. HMOs were
annotated based on retention time and oﬄine mass spectrometry
and quantified based on standard response curves and in relation
to the internal standard. Secretor status was determined based
on presence or near-absence of 2′-FL and lacto-N-fucopentaose
I. Since overall HMO composition differs between Secretors and
Non-secretors, HMO were compared between the HW and NW
for Secretors and Non-secretors combined as well as stratified by
TABLE 1 | Maternal and child characteristics according to high weight gain (HW)
or normal weight gain (NW) groupa.
Infant Characteristics HW group NW group p-valueb
At birth
N 13 17
Gender (girls) n(%) 5 (38.5) 10 (58.8) 0.27
Gestational age, weeks 40.7 (40.5, 41.1) 40.4 (39.7, 41.3) 0.42
Cesarean delivery, n(%) 4 (33.3) 2 (11.8) 0.20
Weight, kg 3.99 ± 0.41 3.55 ± 0.31 0.006
Length, cm 53.0 ±1.4 51.7 ±1.7 0.045
Weight-for-age z-score 1.32 ± 0.75 0.54 ± 0.61 0.006
BMI-for-age z-score 0.56 ± 0.80 −0.08 ± 0.59 0.025
5 month visit
N 13 17
Age, months 5.6 ±0.5 5.9 ±0.3 0.054
Weight, kg 10.60 ±0.88 7.89 ±0.50 <0.001
Length, cm 70.5 ±2.2 68.1 ±2.1 0.009
Weight-for-age z-score 3.02 ± 0.76 0.39 ± 0.55 <0.001
BMI-for-age z-score 2.49 ± 0.99 −0.09 ± 0.83 <0.001
Fat mass percentage, % 35.40 ± 3.18 27.78 ± 3.14 <0.001
Weight velocity birth to 5
month visit, g/w
271.9 ±32.4 169.2 ±17.1 <0.001
WAZ change from birth to
5 month visit
1.71 ± 0.69 −0.15 ± 0.68 <0.001
24 h milk intake, g 981.9
(653.8–1321.4)
852.0
(482.7–1234.7)
0.19
9 month visit
N 12 17
Age, months 9.0 ±0.3 9.1 ±0.2 0.48
Weight, kg 11.65 ±0.79 9.03 ±0.37 <0.001
Length, cm 75.7 ±1.9 72.5 ±2.0 <0.001
Weight-for-age z-score 2.63 ± 0.56 0.47 ± 0.49 <0.001
BMI-for-age z-score 2.06 ± 0.89 0.15 ± 0.80 <0.001
Fat mass percentage, % 36.12 ± 3.50 31.02 ± 2.26 <0.001
Weight velocity 5 to 9
month visit, g/w
80.4 ±22.47 81.9 ±20.76 0.93
WAZ change from 5 to 9
month visit
−0.30 ± 0.34 0.08 ± 0.29 0.004
Maternal Characteristics
Age, years 32.5 ±3.9 33.7 ±3.2 0.40
Parity, >1 (%) 53.9 52.9 0.96
Pre-pregnancy weight, kg 71.9 ±12.0 60.6 ±6.0 0.002
Height, cm 170.2 ±5.5 165.8 ±7.3 0.077
Pre-pregnancy BMI,
kg/m2
24.2 (22.1, 26.6) 22.2 (21.2, 22.5) 0.082
Gestational weight gain,
kg
14 (12, 17) 15 (13, 18) 0.400
Weight, kg at 5 months 75.7 ±16.8 62.2 ±5.5 0.004
Weight, kg at 9 months 70.9 ±15.9 61.9 ±5.9 0.053
aValues are expressed as mean ± standard deviation, median (25th, 75th percentile) or
number (percentage) as appropriate. HW, high weight-gain group; NW, normal weight-
gain group.
bp-values for differences between groups analyzed by Fisher’s exact Chi-squared test for
proportions, by independent t-test for age at visit, and by linear model adjusted for sex
for all other variables. Bold values indicate significance at a P < 0.05 level.
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TABLE 2 | Human milk oligosaccharides content and 24 h intake according to high weight gain (HW) or normal weight gain (NW) groups, including only Secretors at 5
and 9 monthsa.
HMOs Concentration (nmol/L) Absolute intake (mg/d)
HW NW p-value HW NW p-value
Secretor, n yes (%)
5 mo 8 (72) 15 (87)
9 mo 6 (75) 12 (86)
Fucosylated or sialylated lactose
2
′
-FL
5 mo 8360 (7045, 10276) 6126 (5112, 7000) 0.061 3885 (2933, 5460) 2360 (1987, 3693) 0.096
9 mo 8201 (6269, 10962) 5191 (4228, 7598) 0.160
3-FL
5 mo 479 (422, 676) 470 (355, 577) 0.519 226 (187, 331) 191 (142, 298) 0.346
9 mo 709 (673, 773) 672.86 (400.55, 920.70) 0.851
DFLac
5 mo 888 (850, 1005) 781 (593, 868) 0.045 628 (421, 725) 389 (267, 567) 0.082
9 mo 1221.27 (945.75, 1587.07) 978.96 (769.49, 1358.50) 0.223
3
′
-SL
5 mo 896 (818, 1030) 777 (614, 1042) 0.401 556 (413, 717) 407 (318, 584) 0.218
9 mo 1104 (1004, 1373) 1125 (700, 1716) 0.851
6
′
-SL
5 mo 21 (193, 246) 247 (227, 315) 0.071 145 (116, 157) 128 (105, 163) 0.942
9 mo 102.51 (87.59, 205.27) 148.70 (116.79, 207.36) 0.512
Non-fucosylated, non-sialylated HMOs
LNT
5 mo 1109 (768, 1475) 1340 (1064, 1511) 0.333 845 (637, 915) 700 (555, 922) 0.942
9 mo 598 (477, 669) 706 (502, 1344) 0.399
LNnT
5 mo 592 (525, 649) 817 (689, 974) 0.012 399 (330, 509) 438 (380, 620) 0.311
9 mo 424 (365, 543) 736 (504, 1061) 0.049
LNH
5 mo 84 (74, 96) 101 (76, 144) 0.175 76 (62, 108) 91 (80, 122) 0.772
9 mo 43 (41, 87) 43 (33, 62) 0.512
Fucosylated, non-sialylated HMOs
LNFP I
5 mo 680 (552, 894) 932 (449, 1782) 0.846 585 (411, 708) 956 (286, 1184) 0.612
9 mo 723 (576, 786) 684 (470, 1258) 0.925
LNFP II
5 mo 1656 (1496, 2251) 1926 (1415, 2217) 0.796 1553 (1180, 1790) 1191 (909, 1696) 0.515
9 mo 1436 (1291, 1535) 1445 (1220, 2154) 0.708
LNFP III
5 mo 68 (59, 85) 91 (77, 132) 0.071 65 (47, 80) 65 (58, 83) 0.717
9 mo 82 (65, 96) 96 (84, 115) 0.160
DFLNT
5 mo 1565 (1410, 1601) 1486 (1422, 1720) 0.949 1354 (1140, 1622) 1213 (994, 1489) 0.247
9 mo 1863 (1531, 1992) 1827 (1590, 2054) 0.851
FLNH
5 mo 36 (26, 40) 39 (32, 69) 0.197 40 (31, 46) 40 (35, 59) 0.515
9 mo 16 (16, 19) 17 (10, 27) 1.000
DFLNH
5 mo 15 (13, 20) 25 (17, 50) 0.045 20 (18, 26) 36 (17, 54) 0.070
9 mo 14 (13, 18) 15 (12, 29) 0.640
(Continued)
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TABLE 2 | Continued
HMOs Concentration (nmol/L) Absolute intake (mg/d)
HW NW p-value HW NW p-value
Non-fucosylated, sialylated HMOs
LSTb
5 mo 111 (80, 159) 149 (115, 160) 0.333 111 (88, 132) 123 (80, 145) 0.612
9 mo 132 (70, 208) 158 (148, 182) 0.512
LSTc
5 mo 31 (12, 33) 33 (15, 42) 0.175 23 (11, 35) 26 (14, 31) 1.000
9 mo 12.67 (8.11, 17.41) 8.62 (6.29, 16.38) 0.851
DSLNT
5 mo 275 (213, 389) 311 (253, 375) 0.606 308 (265, 512) 293 (262, 481) 0.664
9 mo 413 (252, 553) 395 (372, 437) 0.851
DSLNH
5 mo 24 (16, 43) 37 (20, 52) 0.220 43 (26, 57) 59 (18, 71) 0.385
9 mo 4 (4, 7) 15 (8, 27) 0.190
Fucosylated, sialylated HMOs
FDSLNH
5 mo 184 (135, 257) 326 (168, 404) 0.061 337 (223, 537) 503 (225, 586) 0.515
9 mo 139 (12, 158) 223 (147, 367) 0.111
HMO-bound Fucose
5 mo 16580 (15740, 17856) 14981 (14196, 15786) 0.033
9 mo 18115 (16353, 19416) 14994 (14137, 17079) 0.049
HMO-bound Sialic acid
5 mo 2176 (1993, 2678) 2743 (2276, 2974) 0.366
9 mo 2413 (2135, 2989) 2784 (2583, 3378) 0.261
HMO sum
5 mo 17602 (17022, 18474) 16584 (15656, 17199) 0.061 11039 (8707, 14336) 9832 (8054, 11430) 0.277
9 mo 17771 (16462, 19312) 15623 (15134, 17773) 0.061
Diversity
5 mo 3.92 (3.06, 4.67) 5.48 (4.85, 5.92) 0.061
9 mo 4.10 (2.98, 5.19) 6.01 (4.39, 6.78) 0.160
aData is presented for Secretors only as median (IQR) and tested using Mann-Whitney U-test. mo, months; 2′-FL, 2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-
SL, 6′-sialyllactose; LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose; LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac,
difucosyl-lactose; DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-
hexaose; DSLNH, disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides. Bold values indicate significance at a P < 0.05 level.
secretor status. However, as there was only a very few infants in
the Non-secretor group this was not examined separately. HMO
concentrations permLweremultiplied with total 24 hmilk intake
volume to yield absolute HMO intake per 24 h. To assess the
overall diversity of HMO composition, Simpson’s Diversity index
was calculated as the reciprocal sum of the square of the relative
abundance of each HMO.
Statistical Analysis
Statistical analyses were performed using the R statistical
environment (http://cran.r-project.org/, version 3.4.0).
Descriptive results are presented as means and SD, mean
and range or median and interquartile range (IQR: 25th and 75th
percentile) as appropriate.
Differences between groups baseline characteristics was
analyzed by Fisher’s exact Chi-squared test for proportions,
by independent t-test for age at visit, and by linear model
adjusted for sex for all other variables. Mann-Whitney U-
test was used to test differences between the two study
groups, as HMO concentrations were not normally distributed.
Associations between the different HMOs and infant WAZ,
BMI-for-age z-scores (BAZ) and height-for-age z-scores (HAZ),
fat mass index (FMI), fat free mass index (FFMI) and weight
velocity from birth to 5 months as well as associations
between mothers BMI, gestational weight gain and HMOs
were investigated by Spearman’s correlation, for the groups
combined. We did not adjust for multiple confounders
since this was not feasible given the small sample size.
We used both raw and Benjamini-Hochberg false discovery
rate–corrected P-values. In line with the explorative nature
of the work we treated results with a raw P < 0.05
as being of interest. None of the false discovery rate–
corrected P-values were <0.05 and we have only reported
raw p-values.
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RESULTS
Mother and Child Characteristics
Infants in the HW group weighed ∼450 g more and were 1.3 cm
longer at birth than the NW group (Table 1). From birth to the
5 months visit weight gain was excessive in the HW group with
about 100 g/week more than the NW group (p < 0.001). From
the 5 to the 9 months visit weight gain per week was the same in
the two groups (about 80 g/week, Table 1), but WAZ decreased
in the HW group and was unchanged in the NW group. The BAZ
decreased from 5 to 9 months from 2.49 to 2.06 in the HW group.
Themothers in the two groups were of the same age and the same
percentage was primipara (Table 1). The mothers in the HW
group had higher body weight pre-pregnancy and at 5 months,
but there was no difference in BMI either pre-pregnancy or at
5 months. The mean duration of exclusive or full breastfeeding
for the HW and NW group, were 5.14 months (range: 3.69–6.46)
and 5.54 months (range: 3.46–6.46), respectively (p = 0.29). At 9
months 83% of the infants in the HW and 94% in the NW group
were still breastfed (p= 0.56).
Mean 24 h milk intake was 130 g (15%) higher in the HW
group, but the difference was not significant (Table 1) and there
was no difference in human milk intake per kg per day between
the groups (data not shown). At the 5 months visit 73% of the
infants in the HW group and all infants in the NW group were
introduced to complementary feeding (p = 0.064). The median
contribution of complementary feeding to the total energy intake
did not differ between the HW group and the NW group (15.9 vs.
23.0%, p= 0.37).
Differences in HMO Composition Between
HW and NW Groups
Human milk oligosaccharide (HMO) composition in Secretor
and Non-secretor mothers differ significantly (17). Thus, HMO
data were compared between the HW and NW; first stratified by
secretor status and subsequently for Secretors and Non-secretors
combined. Eight out of the 11 mothers with infants in the HW
group and 15 of the 17 mothers with infants in the NW group
were Secretors. As there were only five Non-secretors in total, we
did not do separate analysis for these.
Differences in HMO content between the HW and NW
groups at 5 and 9 months in milk from Secretor mothers
alone are shown in Table 2. At 5 months, total HMO-bound
fucose (p = 0.033) and DFLac (P = 0.045) were higher in
the HW group compared to the NW group, whereas DFLNH
(p = 0.045) and LNnT (p = 0.012) were lower in the HW
group. No differences were observed for other HMOs. Total
HMO-bound fucose remained significantly higher and LNnT
concentrations remained significantly lower in the HW group at
9 months compared to the NW group, whereas no differences
were observed for other HMOs. The most abundant HMO,
2′-FL was 36% higher in the HW group, but the difference
was only borderline significant (p = 0.061). Overall, the results
were similar between testing absolute concentrations and relative
abundance of HMOs (data not shown).
At 5 months, when combining Secretors and Non-secretors,
LNnT concentrations were lower in the HW group (P = 0.046),
similarly as for Secretors only (Supplemental Table 1).
Additionally, LSTc concentrations (P = 0.041) and HMO
diversity (P = 0.041) were lower in the HW group compared to
the NW group. No differences were observed at 9 months.
When also considering the 24 h milk volume, there were no
differences between the groups for absolute intake of HMOs
(mg/d) at 5 months.
Associations Between HMO Composition
and Growth
Associations between HMO composition and anthropometry
at 5 months and weight velocities from birth to 5 months
TABLE 3 | Spearman correlations between human milk oligosaccharide content
and Height-for-Age Z-scores (HAZ) and BMI-for-Age Z-scores (BAZ) at 5 months
(Secretors only)a.
HMOs HAZ BAZ
Rho p-value Rho p-value
Fucosylated or sialylated lactose
2′-FL 0.238 0.275 0.388 0.067
3-FL 0.221 0.311 0.209 0.338
DFLac 0.501 0.015 0.128 0.562
3′-SL 0.461 0.027 −0.014 0.948
6SL −0.222 0.309 −0.438 0.036
Non-fucosylated, non-sialylated HMOs
LNT −0.217 0.319 −0.225 0.301
LNnT −0.541 0.008 −0.330 0.125
LNH 0.047 0.83 −0.221 0.311
Fucosylated, non-sialylated HMOs
LNFP I −0.296 0.171 0.051 0.818
LNFP II 0.139 0.527 −0.046 0.833
LNFP III −0.290 0.180 −0.248 0.255
DFLNT 0.218 0.317 −0.115 0.602
FLNH −0.097 0.660 −0.340 0.112
DFLNH −0.475 0.022 −0.403 0.057
Non-fucosylated, sialylated HMOs
LSTb −0.186 0.396 −0.040 0.856
LSTc −0.334 0.119 −0.202 0.355
DSLNT −0.176 0.422 0.040 0.856
DSLNH 0.006 0.977 −0.329 0.126
Fucosylated, sialylated HMOs
FDSLNH −0.020 0.927 −0.343 0.109
HMO-bound fucose 0.374 0.079 0.357 0.094
HMO-bound sialic acid 0.121 0.582 −0.135 0.539
HMO sum 0.230 0.290 0.379 0.074
Diversity −0.240 0.271 −0.378 0.075
aData are Spearman’s correlation coefficient Rho and p-values. mo, months; 2′-FL,
2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose;
LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose;
LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac, difucosyl-
lactose; DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-
lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-
hexaose; DSLNH, disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides. Bold
values indicate significance at a P < 0.05 level.
Frontiers in Pediatrics | www.frontiersin.org 6 July 2019 | Volume 7 | Article 297
Larsson et al. HMOs and Weight-Gain During Breastfeeding
TABLE 4 | Spearman correlations between human milk oligosaccharide content
and weight velocity from 0 to 5 months (grams per week) (Secretors only)a.
HMOs Weight velocity 0–5 mo (grams pr. week)
Rho p-value
Fucosylated or sialylated lactose
2′-FL 0.500 0.015
3-FL 0.330 0.124
DFLac 0.417 0.048
3′-SL 0.261 0.229
6′-SL −0.302 0.161
Non-fucosylated, non-sialylated HMOs
LNT −0.375 0.078
LNnT −0.531 0.009
LNH −0.134 0.541
Fucosylated, non-sialylated HMOs
LNFP I −0.102 0.644
LNFP II −0.016 0.943
LNFP III −0.285 0.188
DFLNT −0.044 0.840
FLNH −0.268 0.217
DFLNH −0.502 0.015
Non-fucosylated, sialylated HMOs
LSTb −0.197 0.368
LSTc −0.183 0.404
DSLNT −0.142 0.517
DSLNH −0.181 0.409
Fucosylated, sialylated HMOs
FDSLNH −0.243 0.264
HMO-bound fucose 0.565 0.005
HMO-bound sialic acid −0.042 0.847
HMO sum 0.496 0.016
Diversity −0.468 0.024
aData are Spearman’s correlation coefficient Rho and p-values. mo, months; 2′-FL,
2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose;
LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose;
LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac, difucosyl-
lactose; DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-
lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-
hexaose; DSLNH, disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides. Bold
values indicate significance at a P < 0.05 level.
were analyzed by combining the HW and NW group
and excluding Non-secretors (Tables 3–5). Additional
analyses were done combining Secretors and Non-secretors
(Supplemental Tables 2–4).
2′-FL, the most abundant HMO, was positively associated
with 0–5 months weight velocity (p = 0.015) and with FMI at
5 months (p = 0.024) (Figure 1). A similar direction for the
association with change in WAZ from birth to 5 months was
seen, but it did not reach statistical significance (Rho = 0.355,
p = 0.09). DFLac was also positively associated with weight
velocity (p = 0.048) and with length at 5 months (p = 0.015).
3′-SL was positively associated with length at 5 months (p =
0.027). 6′SL was the only HMO in the group of fucosylated
or sialylated lactose HMOs which was inversely associated with
TABLE 5 | Spearman correlations between human milk oligosaccharide content
and fat mass index (FMI) and fat free mass index (FFMI) at 5 months (Secretors
only)a.
HMOs FMI 5 mo FFMI 5 mo
Rho p-value Rho p-value
Fucosylated or sialylated lactose
2′-FL 0.468 0.024 0.245 0.259
3-FL 0.278 0.200 0.008 0.970
DFLac 0.280 0.196 −0.071 0.749
3′-SL 0.117 0.596 −0.247 0.256
6′-SL −0.373 0.080 −0.338 0.115
Non-fucosylated, non-sialylated HMOs
LNT −0.304 0.158 −0.061 0.783
LNnT −0.447 0.033 −0.139 0.526
LNH −0.241 0.268 −0.294 0.173
Fucosylated, non-sialylated HMOs
LNFP I 0.002 0.993 0.261 0.228
LNFP II −0.055 0.802 −0.158 0.472
LNFP III −0.331 0.123 −0.212 0.333
DFLNT −0.100 0.650 −0.132 0.547
FLNH −0.406 0.054 −0.223 0.307
DFLNH −0.434 0.039 −0.192 0.381
Non-fucosylated, sialylated HMOs
LSTb −0.116 0.599 0.040 0.858
LSTc −0.250 0.250 −0.206 0.345
DSLNT −0.056 0.799 0.114 0.605
DSLNH −0.323 0.133 −0.398 0.060
Fucosylated, sialylated HMOs
FDSLNH −0.342 0.110 −0.424 0.044
HMO-bound fucose 0.489 0.018 0.155 0.479
HMO-bound sialic acid −0.129 0.556 −0.275 0.204
HMO sum 0.466 0.025 0.228 0.295
Diversity −0.444 0.034 −0.256 0.239
aData are Spearman’s correlation coefficient Rho and p-values. mo, months; 2′-FL,
2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose;
LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose;
LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac, difucosyl-
lactose; DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-
lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-
hexaose; DSLNH, disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides. Bold
values indicate significance at a P < 0.05 level.
anthropometry. It was inversely associated with BAZ at 5 months
(p = 0.036) and tended to be inversely associated with FMI at 5
months (p= 0.08).
In the group of non-fucosylated, non-sialylated HMOs, only
LNnT was associated with anthropometry. There was an inverse
association with length (p = 0.008), with weight velocity (p =
0.009) and FMI (p = 0.033) (Figure 2). Again a trend for an
inverse association with change in WAZ from birth to 5 months
was observed (Rho = −0.389, p = 0.07). When combining
Secretors and Non-secretors, LNnT was still inversely associated
with length (p= 0.018, Supplemental Table 2).
Total HMO-bound fucose was positively associated with
weight velocity 0–5 months (p = 0.005) and FMI (p = 0.018)
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FIGURE 1 | Total HMO content (A,B), HMO diversity (C,D), HMO-bound fucose (E,F), and 2′-FL concentration (G,H) at 5 months in relation to fat mass index at 5
months and weight velocity 0–5 months (grams pr. week). Only secretors included. Correlations were calculated using Spearman’s rank correlation, but depicted as
Pearson’s correlation (n = 23). HW = • NW = H.
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FIGURE 2 | Concentration of LNnt at 5 months in relation to fat mass index at 5 months (A), weight velocity from 0 to 5 months (grams pr. week) (B), and
height-for-age Z-score (C). Only Secretors included. Correlations were calculated using Spearman’s rank correlation, but depicted as Pearson’s correlation (n = 23).
HW = • NW = H.
(Figure 1). Total HMO was positively associated with weight
velocity 0–5 months (p = 0.016) and FMI at 5 months (p =
0.025), while the association between these two measures and
HMO diversity were inverse (p = 0.024 and 0.034, respectively)
(Figure 1). Both for total HMO-bound fucose and total HMO a
similar direction for the association with change in WAZ from
birth to 5 months was observed, but it did not reach statistical
significance (Rho = 0.373, p = 0.08 and Rho = 0.338, p =
0.10, respectively).
When combining Secretors and Non-secretors, HMO
diversity was still inversely associated with BAZ (p = 0.046),
weight velocity (p = 0.023) and FMI at 5 months (p = 0.024)
(Supplementary Tables 2–4).
Maternal Determinants of HMO Content
Maternal pre-pregnancy BMI, gestational weight gain, and BMI
at 5 months were examined as potential determinants of HMO
concentration in human milk.
In Secretor women, none of the HMOs were
significantly associated with any of these three maternal
determinants (Table 6).
When combining Secretors and Non-secretors, maternal BMI
at 5 months was significantly negatively associated with 6′-SL (P
= 0.032), and LSTb (P = 0.03), and positively associated with 2′-
FL (P = 0.017), total HMO (P = 0.015), and total HMO-bound
fucose (P = 0.033) (Table 7). Associations with pre-pregnancy
BMI were in the same directions but tended to be weaker than
the associations with maternal BMI at 5 months. We did not
find any associations between any HMOs and weight gain in
pregnancy (A6).
DISCUSSION
The aim of the study was to examine if differences in
oligosaccharide composition in human milk were associated
with the excessive weight gain observed in some exclusively
breastfed infants, which had not been done before. We
found only borderline significant differences between the
HW and NW groups in total HMO concentration and
HMO diversity, indicating higher total HMO and lower
diversity in the HW group. However, concentrations of
several individual HMOs were significantly different between
the two groups suggesting that the variation in HMO
composition could indeed be part of the explanation for
the differences in growth between the two groups. This was
further supported by the results showing that several HMOs
were associated with anthropometry, growth velocity, and
body composition in an analysis combining the HW and
NW groups.
Our results indicate that certain HMOs might play a role
in infant growth, which is in accordance with previously
reported data. In a study by Alderete et al., LNFP I in mother’s
milk was negatively associated with infant weight at both 1
and 6 months of age, and with lean mass and fat mass (FM)
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TABLE 6 | Maternal determinants of HMO content at 5 months (Secretors only)a.
Maternal BMI (5 mo) Prepregnancy BMI Weightgain in pregnancy
HMOs Rho p-value Rho p-value Rho p-value
Fucosylated or sialylated lactose
2′-FL 0.336 0.117 0.279 0.198 −0.010 0.964
3-FL 0.098 0.657 0.039 0.861 0.027 0.903
DFLac 0.116 0.599 0.243 0.264 −0.326 0.129
3′-SL −0.024 0.914 0.080 0.717 −0.149 0.498
6′-SL −0.349 0.103 −0.271 0.211 −0.157 0.475
Non-fucosylated, non-sialylated HMOs
LNT −0.155 0.480 −0.049 0.823 0.035 0.873
LNnT −0.123 0.578 −0.202 0.356 0.249 0.251
LNH −0.190 0.386 −0.151 0.491 0.071 0.748
Fucosylated, non-sialylated HMOs
LNFP I 0.100 0.650 −0.039 0.861 0.131 0.550
LNFP II −0.167 0.446 −0.055 0.802 −0.132 0.549
LNFP III −0.104 0.638 −0.139 0.526 0.216 0.322
DFLNT −0.379 0.074 −0.225 0.301 −0.233 0.284
FLNH −0.032 0.886 0.029 0.897 0.131 0.550
DFLNH 0.122 0.581 −0.072 0.744 0.226 0.301
Non-fucosylated, sialylated HMOs
LSTb −0.256 0.239 −0.268 0.217 0.055 0.805
LSTc 0.086 0.697 0.086 0.697 0.166 0.449
DSLNT −0.163 0.457 −0.121 0.584 −0.001 0.996
DSLNH −0.164 0.455 −0.003 0.989 0.062 0.777
Fucosylated, sialylated HMOs
FDSLNH −0.180 0.412 −0.155 0.480 0.072 0.744
HMO-bound fucose 0.285 0.188 0.273 0.208 −0.152 0.488
HMO-bound sialic acid −0.299 0.165 −0.204 0.352 −0.021 0.923
HMO sum 0.374 0.079 0.308 0.152 −0.030 0.893
Diversity −0.321 0.135 −0.266 0.220 −0.029 0.896
aData are Spearman’s correlation coefficient Rho and p-values. mo, months; 2′-FL, 2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose; LNT,
lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose; LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac, difucosyl-lactose;
DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-hexaose; DSLNH,
disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides.
at 6 months of age. In contrast, DSLNT and LNFP II were
positively associated with FM at 6 months, whereas, FDSLNH
and LNnT were associated with higher and lower %FM at
6 months, respectively. Further, at 6 months DSLNT was
negatively associated with body length (6). The group also
reported that higher HMO diversity at 1 month was associated
with lower %FM and FM at 1 month. In accordance with these
findings, we found HMO diversity to be inversely associated
with FMI at 5 months. These findings could indicate that HMO
diversity influences infant body composition during exclusive
breastfeeding. Furthermore, HMO diversity was also associated
with weight velocity in our study and diversity was considerably
lower in the HW group (3.92 vs. 5.48), but only borderline
significant. However, Sprenger et al. found no differences
in infant anthropometric measurements between infants
consuming human milk with low or high fucosyltransferase
2 (FUT2, secretor) genotype-associated HMO concentrations
or composition in a group of 50 mother-infants dyads (18).
However, their study did not analyze HMOs that are independent
of FUT2.
The only HMO that was linked to growth in both our study
and the Alderete study was LNnT. In both studies it seems to
be related to lower FM% as Alderete et al. (6) found negatively
associations with FM% and we found lower values of LNnT in
the HW group, which had a significantly higher %FM compared
to the NW group. Furthermore, we found a negative association
of LNnT with FMI at 5 months. LNnT has been shown to alter
the gut microbiota in humans, which could explain why it is
associated with growth (19).
The most plausible mechanism linking HMOs and growth
is that HMOs play a role in developing the infant microbiome.
Without being degraded by the infant digestive system, HMOs
reach distal parts of the infant’s intestine where they are
metabolized by the intestinal microbiota (20). The gutmicrobiota
might potentially play a role in energy harvest from the diet
and in energy storage for the host and has been associated
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TABLE 7 | Maternal determinants of HMO content at age 5 months (Secretors and Non-secretors combined)a.
HMOs Maternal BMI (5 mo) Prepregnancy BMI Weightgain in pregnancy
Rho p-value Rho p-value Rho p-value
Fucosylated or sialylated lactose
2′-FL 0.446 0.017 0.389 0.041 0.027 0.893
3-FL 0.299 0.122 0.235 0.229 0.069 0.726
DFLac 0.301 0.120 0.346 0.071 −0.176 0.371
3′-SL 0.172 0.382 0.218 0.264 −0.025 0.901
6′-SL −0.406 0.032 −0.323 0.094 −0.131 0.507
Non-fucosylated, non-sialylated HMOs
LNT −0.327 0.089 −0.230 0.238 −0.059 0.765
LNnT −0.177 0.368 −0.224 0.251 0.117 0.552
LNH 0.078 0.692 0.078 0.692 0.155 0.431
Fucosylated, non-sialylated HMOs
LNFP I 0.299 0.122 0.195 0.319 0.130 0.51
LNFP II −0.361 0.059 −0.278 0.152 −0.161 0.413
LNFP III −0.198 0.314 −0.211 0.28 0.097 0.624
DFLNT −0.055 0.782 0.061 0.759 −0.161 0.414
FLNH 0.158 0.421 0.198 0.314 0.319 0.098
DFLNH 0.019 0.923 −0.131 0.507 0.203 0.300
Non-fucosylated, sialylated HMOs
LSTb −0.411 0.030 −0.403 0.034 −0.031 0.875
LSTc 0.342 0.075 0.325 0.091 0.217 0.267
DSLNT −0.182 0.355 −0.152 0.440 −0.022 0.911
DSLNH −0.203 0.300 −0.063 0.748 0.026 0.896
Fucosylated, sialylated HMOs
FDSLNH −0.257 0.187 −0.242 0.215 0.108 0.583
HMO-bound fucose 0.404 0.033 0.373 0.051 −0.054 0.787
HMO-bound sialic acid −0.276 0.155 −0.215 0.272 0.032 0.871
HMO sum 0.455 0.015 0.393 0.039 0.019 0.925
Diversity −0.257 0.187 −0.231 0.237 0.032 0.870
aData are Spearman’s correlation coefficient Rho and p-values. mo, months; 2′-FL, 2′-fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose; LNT,
lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I-II-III, lacto-N-fucopentaose; LSTb, LSTc, sialyl-lacto-N-tetraose; DSLNT, disialyl-lacto-N-tetraose; DFLac, difucosyl-lactose;
DFLNT, difucosyl-lacto-N-tetraose; LNH, lacto-N-hexaose; FLNH, fucosyl-lacto-N-hexaose; DFLNH, difucosyl-lacto-N-hexaose; FDSLNH, fucosyl-disialyl-lacto-N-hexaose; DSLNH,
disialyl-lacto-N-hexaose; HMOs, human milk oligosaccharides. Bold values indicate significance at a P < 0.05 level.
with overweight and obesity. Studies have shown that a specific
microbiome pattern can have an increased ability to harvest
energy from the diet and thus accelerate growth (5, 21, 22). Other
mechanisms linking HMOs and growth have also been suggested
such as HMOs having direct effects on epithelial cell responses in
the gut or that HMOs have systemic effects, by being absorbed
(partly) intact into circulation (6).
Several studies have shown a distinctively different fecal
microbiota composition in breastfed compared with formula-
fed infants (23, 24). Furthermore, the composition of the
fecal microbiota in breastfed infants were correlated with
the HMO composition in the milk consumed in other
studies (25).
There is increasing interest in adding HMOs to infant
formula in order to optimize the intestinal microbiota and
the development of the immune system. Since HMOs might
influence energy harvest through alterations of the microbiota,
HMOs might also affect growth. Therefore, there has been an
interest in testing if the addition of HMOs to infant formula has
an effect on growth. In a multicenter randomized trial, growth
was compared between two groups of infants (age < 14 days)
randomized to receive either a formula supplemented with LNnT
and 2′-FL or a standard formula, from enrolment to 6 months
of age (7). Weight gain was the same in the two groups and
they concluded that a formula with these two HMOs added
supports age-appropriate growth. Interestingly, we found that in
the human milk the HW group received, LNnT was significantly
lower both at 5 and 9 months, and was strongly negatively
associated with weight velocity from 0 to 5 months and with
length at 5 months (both p < 0.009) in the combined group.
Furthermore, the content of the most abundant HMO, 2′-FL
was 36% higher in the HW group compared to the NW group,
though only borderline significant (p = 0.061), and positively
associated with weight gain from 0 to 5 months and with FMI
at 5 months. Thus, the effect on growth of 2′-FL and LNnT
seems to be opposite, which might be the reason that adding
both of these to a formula did not influence growth (7). However,
another study adding 2′-FL to infant formula showed that infants
in the intervention study had a growth pattern not different
from breastfed infants and a review also concluded that adding
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2′-FL or LNnT seems to support normal growth, although the
data are limited (26, 27). In the two studies adding 2′-FL to
formula the amount was 1.0 g/L (7, 27), which is considerable
lower than the average 2′-FL concentration in our NW (∼3 g/L)
and HW group (∼4 g/L) (Table 2). In the study adding two
HMOs to infant formula (7) the amount of LNnT was 0.5 g/L,
which is about the same concentrations as in human milk in our
NW group.
The potential maternal determinants of HMO concentrations
were examined in an analysis combining the HW and NW
groups. Pre-pregnancy BMI and maternal BMI at the time
of HMO sampling were associated with some HMOs whereas
gestational weight gain was not. These associations were found
in the analysis including both Secretors and Non-secretors
whereas no associations were found in the analysis including
only Secretors.We did not analyze Non-secretors separately since
we only had very few infants in this group. Maternal weight
and body composition have recently been linked to growth in
infancy in 427 mother-infant dyads, showing that LNH and
DFLNT concentrations were higher in overweight and obese
mothers compared with normal weight mothers (17). In our
study, where only few of the mothers were overweight or obese
(11), we found that maternal BMI at 5 months was positively
associated with total HMO, HMO-bound fucose as well as
the most abundant HMO 2′-FL and negatively associated with
LSTb and 6′-SL.
Our study has some limitations with the main limitation being
the small sample size, which limits the power to detect differences
between groups. Furthermore, we did not adjust for multiple
testing as this is an exploratory study and our findings therefore,
need to be verified in other studies. In addition, the study
was a single center study further limiting the generalizability
to other settings. Another limitation is that it was not possible
to identify, recruit, and arrange clinical visits before the age
of 5 to 6 months when growth velocity was decreasing and
some infants had been introduced to complementary foods.
HMO composition is likely to change during the course of
lactation, as shown by Alderete et al. where 13 out of 16 analyzed
HMOs changed significantly from 1 to 6 months post-partum
(6) as well as in a cross-sectional study by Azad et al. (17) that
revealed associations between HMO concentrations and days
of lactation. Therefore, the HMO composition measured at 5–
6 months might not fully reflect the HMO composition during
the entire period where the excessive weight gain took place
(0–5 months). If we had been able to measure HMOs when
growth velocity was considerably higher, it is possible that we
had found stronger associations between growth and HMOs,
but this is speculative. Adjusting for other milk components
such as fat, lactose, and protein content was not possible in
the present study due to the small sample size, however, in an
earlier study, minimal differences between the two groups were
found and thus we think that this is unlikely to have affected the
current results.
An additional limitation of the current study is the lack of
long term follow up that would add additional information on the
long-term effects of the excessive weight gain in early life as well
as associations between HMOs and long-term growth patterns
of children. Finally, long-term follow ups are essential for
understanding the long-term consequences of excessive weight
gain observed in some exclusively breastfed infants.
The strengths of the study are that we use a state of
the art method for assessing HMOs in a well-characterized
cohort. Although the number of participants was low, the
fact that we have included infants with excessive weight gain
and compared them with a group with a normal weight gain
increases the chances of finding associations between HMO
intake and growth. Furthermore, we have estimated data on
total milk intake, which is the first study that not only
looks at HMO concentrations but also computes total HMO
intake considering both concentration and volume. However,
it should be emphasized that milk intake was measured after
the excessive weight gain occurred and is therefore subject to
the same limitations as the HMO content discussed above.
Future studies should be performed in larger samples with
longer follow-up to identify the contribution of specific HMOs
to infant growth and development. Furthermore, the link
between HMOs and gut microbiota in relation to growth should
be investigated simultaneously and in both human studies
and experimental models to confirm a causal link. Moreover,
determinants of HMO concentrations should be investigated
to find potential modifiable factors, which could be targeted
in interventions.
CONCLUSIONS
In conclusion, we found significant differences between HMO
concentrations in a group of exclusively breastfed infants with
high weight gain compared to a group of infants with normal
weight gain, which emphasizes that HMOs play an important
role in infant growth. However, since this is a small explorative
study it cannot proof causality, warranting further in-depth
studies that investigate the role and underlying mechanisms
that link variation in HMO composition to excessive weight
gain. Understanding the link between HMOs and infant body
composition, growth, and potential long-term consequences will
be of paramount importance before individual HMOs are added
to formula fed to infants.
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